Drugs, discipline and death: Causes and predictors of mortality among people who inject drugs in Tijuana, 2011-2018.
Drug policy
Drug treatment
HIV
Injection cessation
Injection drug use
Law enforcement
Mexico
Mortality
Overdose
Violence
Journal
The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
09
04
2019
revised:
17
09
2019
accepted:
10
11
2019
pubmed:
28
11
2019
medline:
30
10
2020
entrez:
28
11
2019
Statut:
ppublish
Résumé
People who inject drugs (PWID) experience multiple risk factors for mortality; yet, we know little about causes of death among PWID in Tijuana, Mexico, an area with high levels of injecting and changes in policy/law enforcement responses to substance use. This study examines rates, causes, and predictors of mortality among Tijuana PWID. Data come from a community-based cohort of PWID aged ≥18 who injected drugs in the past month. Mortality was confirmed by death certificate over 78 months during 2011-2018. Predictors of mortality were identified using time-updated Cox regression, controlling for age. Among 734 participants, there were 130 deaths (54 confirmed, 76 unconfirmed), with an incidence rate of 17.74 deaths per 1000 person-years for confirmed deaths (95% Confidence Interval (CI)=13.01, 22.48) and 39.52 for unconfirmed deaths (CI=32.72, 46.31). Confirmed deaths resulted from homicide/trauma (26%), overdose (26%), septic shock (18%) and HIV-related causes (9%). In multivariable analysis of confirmed deaths, baseline HIV seropositivity (adjusted Hazard Ratio [aHR]=6.77, CI=1.98, 23.17), incident HIV infection (aHR=3.19, CI=1.02, 9.96), and number of times being beaten by police in the past 6 months at baseline (aHR=1.08 per time, CI=1.04, 1.12) were predictive of death; whereas, injection cessation for 6+ months during time at risk (aHR=0.25, CI=0.33, 0.79) was protective. In addition to overdose and HIV prevention efforts, attention to structural conditions that potentiate mortality is needed, including improved access to medication-assisted treatment to support injection cessation and a shift from police as a source of harm to harm reduction.
Sections du résumé
BACKGROUND
People who inject drugs (PWID) experience multiple risk factors for mortality; yet, we know little about causes of death among PWID in Tijuana, Mexico, an area with high levels of injecting and changes in policy/law enforcement responses to substance use. This study examines rates, causes, and predictors of mortality among Tijuana PWID.
METHODS
Data come from a community-based cohort of PWID aged ≥18 who injected drugs in the past month. Mortality was confirmed by death certificate over 78 months during 2011-2018. Predictors of mortality were identified using time-updated Cox regression, controlling for age.
RESULTS
Among 734 participants, there were 130 deaths (54 confirmed, 76 unconfirmed), with an incidence rate of 17.74 deaths per 1000 person-years for confirmed deaths (95% Confidence Interval (CI)=13.01, 22.48) and 39.52 for unconfirmed deaths (CI=32.72, 46.31). Confirmed deaths resulted from homicide/trauma (26%), overdose (26%), septic shock (18%) and HIV-related causes (9%). In multivariable analysis of confirmed deaths, baseline HIV seropositivity (adjusted Hazard Ratio [aHR]=6.77, CI=1.98, 23.17), incident HIV infection (aHR=3.19, CI=1.02, 9.96), and number of times being beaten by police in the past 6 months at baseline (aHR=1.08 per time, CI=1.04, 1.12) were predictive of death; whereas, injection cessation for 6+ months during time at risk (aHR=0.25, CI=0.33, 0.79) was protective.
CONCLUSION
In addition to overdose and HIV prevention efforts, attention to structural conditions that potentiate mortality is needed, including improved access to medication-assisted treatment to support injection cessation and a shift from police as a source of harm to harm reduction.
Identifiants
pubmed: 31775080
pii: S0955-3959(19)30308-1
doi: 10.1016/j.drugpo.2019.11.009
pmc: PMC6957706
mid: NIHMS1544641
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102601Subventions
Organisme : NIDA NIH HHS
ID : DP2 DA040256
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009343
Pays : United States
Organisme : NIDA NIH HHS
ID : K01 DA041233
Pays : United States
Organisme : NIDA NIH HHS
ID : R37 DA019829
Pays : United States
Organisme : NIDA NIH HHS
ID : K01 DA043421
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.
Références
J Immigr Minor Health. 2012 Feb;14(1):48-64
pubmed: 21789558
Soc Sci Med. 2003 Aug;57(3):561-9
pubmed: 12791497
Int J Drug Policy. 2014 Jan;25(1):105-11
pubmed: 23916801
Bull World Health Organ. 2013 Feb 1;91(2):102-23
pubmed: 23554523
Addiction. 2016 Jul;111(7):1246-56
pubmed: 26879179
AIDS Care. 2006 Jan;18(1):1-11
pubmed: 16282070
Addiction. 2011 Feb;106(2):357-65
pubmed: 21054615
AIDS Care. 2006 Feb;18(2):101-8
pubmed: 16338767
Addiction. 2011 Mar;106(3):583-9
pubmed: 21054619
Lancet. 2018 Aug 18;392(10147):553-554
pubmed: 30152386
J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):351-7
pubmed: 11707672
AIDS Behav. 2016 May;20(5):1017-25
pubmed: 26354518
Lancet. 2012 Jan 7;379(9810):55-70
pubmed: 22225671
Soc Sci Med. 1997 Oct;45(8):1161-76
pubmed: 9381230
J Infect Dis. 2004 Sep 15;190(6):1046-54
pubmed: 15319852
Drug Alcohol Depend. 2007 Nov 2;91(1):50-6
pubmed: 17561355
Int J Drug Policy. 2017 Dec;50:82-89
pubmed: 29040841
Med Anthropol. 1997 Dec;18(1):61-83
pubmed: 9458668
AIDS Behav. 2017 Apr;21(4):1044-1053
pubmed: 28063072
Addiction. 2004 Aug;99(8):946-54
pubmed: 15265091
J Urban Health. 2006 Nov;83(6):1114-26
pubmed: 16977494
J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):369-76
pubmed: 18176320
AIDS. 2014 Nov;28 Suppl 4:S435-44
pubmed: 25409098
Int J Drug Policy. 2014 May;25(3):525-32
pubmed: 24418632
AIDS. 2012 Feb 20;26(4):403-17
pubmed: 22112599
Lancet Public Health. 2018 Sep;3(9):e429-e437
pubmed: 30122559
BMC Public Health. 2015 Feb 07;15:106
pubmed: 25884182
Am J Epidemiol. 2016 Mar 15;183(6):544-52
pubmed: 26865265
Soc Sci Med. 2005 Aug;61(3):673-84
pubmed: 15899325
Addiction. 2012 Jan;107(1):215-22
pubmed: 21831178
Curr Opin HIV AIDS. 2016 Sep;11(5):507-513
pubmed: 27254749
Addiction. 2018 Jun;113(6):1056-1063
pubmed: 29333664
JAMA Intern Med. 2018 Sep 1;178(9):1153-1154
pubmed: 30073242
Harm Reduct J. 2014 Feb 12;11:4
pubmed: 24520885
Drug Alcohol Depend. 2015 Sep 1;154:243-50
pubmed: 26208792
Rev Saude Publica. 2008 Apr;42(2):249-55
pubmed: 18372975
Int J Drug Policy. 2014 May;25(3):608-15
pubmed: 24332972
PLoS One. 2013 Dec 12;8(12):e82476
pubmed: 24349294
Am J Epidemiol. 1996 Feb 15;143(4):380-91
pubmed: 8633622
Drug Alcohol Depend. 2008 Jan 1;92(1-3):132-40
pubmed: 17714888
Am J Public Health. 2005 Feb;95(2):233-6
pubmed: 15671455
J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):116-8
pubmed: 14501805
Drug Alcohol Depend. 2015 Mar 1;148:221-5
pubmed: 25655577
Addiction. 2011 Aug;106(8):1437-45
pubmed: 21438941
Ann Epidemiol. 2012 Jun;22(6):426-38
pubmed: 22626001
J Addict Med. 2010 Dec;4(4):217-22
pubmed: 21769039
Lancet. 2010 Aug 14;376(9740):493-5
pubmed: 20650521
Drug Alcohol Depend. 2008 Aug 1;96(3):281-5
pubmed: 18434044
PLoS One. 2013;8(2):e57201
pubmed: 23437341
Harm Reduct J. 2007 Jan 04;4:1
pubmed: 17201933
Lancet. 2010 Jul 24;376(9737):268-84
pubmed: 20650523
Salud Publica Mex. 2006 Mar-Apr;48(2):141-50
pubmed: 16619870
J Urban Health. 2013 Apr;90(2):284-98
pubmed: 22806453
Am J Epidemiol. 2012 Feb 15;175(4):302-8
pubmed: 22227793
J Urban Health. 2002 Jun;79(2):266-77
pubmed: 12023502
Addiction. 2007 Mar;102(3):441-6
pubmed: 17298652
Drug Alcohol Depend. 2011 Jun 1;115(3):190-5
pubmed: 21130585
Soc Sci Med. 2002 Jul;55(2):247-56
pubmed: 12144139